(Q36958358)

17 August 2017

1 reference

title

Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality? (English)

1 reference

17 August 2017

1 reference

2

Yehuda Shoenfeld

1 reference

17 August 2017

1

Maya Ram

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

Annals of the New York Academy of Sciences

17 August 2017

published in

1 reference

17 August 2017

volume

1110

1 reference

17 August 2017

page(s)

410-425

1 reference

Human melanocyte biology, toxicology, and pathology

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.043

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.043

MART-1 is required for the function of the melanosomal matrix protein PMEL17/GP100 and the maturation of melanosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.043

Tyrosinase stabilization by Tyrp1 (the brown locus protein).

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.043

Mutations in dopachrome tautomerase (Dct) affect eumelanin/pheomelanin synthesis, but do not affect intracellular trafficking of the mutant protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.043

Antibodies to normal human melanocytes in vitiligo

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.043

Vitiligo autoantibodies are effective against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.043

Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.043

Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.043

Multiple pathways to tumor immunity and concomitant autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.043

Serum antibodies in vitiligo patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.043

Therapeutic implications of autoimmune vitiligo T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.043

Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.043

Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.043

Transfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.043

A symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.043

Immunotherapy of malignant melanoma – Basic principles and novel therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.043

21 January 2018

Identifiers

DOI

10.1196/ANNALS.1423.043

1 reference

17 August 2017

1 reference